

Endoscopic ultrasound guided pancreatic tissue sampling (SharkBITE Study)

Submission date 10/04/2017	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/05/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 04/07/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-comparing-2-needles-doctors-use-to-take-a-sample-of-pancreatic-tissue-the-sharkbite-study>

Contact information

Type(s)

Public

Contact name

Ms Hannah Stevenson

Contact details

Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN
+44 191 2138429
hannah.stevenson@nuth.nhs.uk

Type(s)

Scientific

Contact name

Dr Kofi Oppong

ORCID ID

<https://orcid.org/0000-0002-7381-7412>

Contact details

Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN
+44 191 2138429
Kofi.Oppong@nuth.nhs.uk

Additional identifiers

ClinicalTrials.gov (NCT)
NCT03532347

Protocol serial number
33281

Study information

Scientific Title

SharkCore biopsy needle versus standard FNA needle in the diagnosis of solid pancreatic masses a randomised controlled cross-over trial of endoscopic ultrasound guided tissue acquisition - The SharkBITE study

Acronym

SharkBITE

Study objectives

The aim of this study is to compare the performance of a standard fine needle aspiration needle and the Sharkcore biopsy needle in endoscopic ultrasound guided pancreatic tissue sampling.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North East - Newcastle & North Tyneside 1 Research Ethics Committee, 08/02/2017, ref: 16/NW/0082

Study design

Randomised; Interventional; Design type: Diagnosis, Device

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Specialty: Gastroenterology, Primary sub-specialty: Gastroenterology; UKCRC code/ Disease: Cancer/ Malignant neoplasms of digestive organs

Interventions

Adult patients with a solid pancreatic mass of any size, requiring EUS guided tissue sampling to make a diagnosis will be eligible to participate. Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for transgastric puncture. Randomisation will be via a computer generated list of allocations provided by the statistician to the trial in advance of the study. Whenever a participant is recruited the list will be referred to see what their treatment order is. All procedures will be performed/supervised by expert endosonographers. Samples will be interpreted by 2 separate groups of pathologists. The pathologists reporting the samples will be blinded to the results with the alternative device. Each participant's involvement in the study will continue for 7 days post procedure to allow for monitoring for adverse events. There will be a telephone call after 7 days to ascertain any post procedure adverse event. Study duration is envisaged as 16 months comprising 10 months recruitment and 6 months follow up.

Intervention Type

Other

Primary outcome(s)

Diagnostic performance of the 2 needle types will be measured by comparing the sensitivity of standard Beacon FNA needle to the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.

Key secondary outcome(s)

1. Adequacy of the samples obtained as reported by the pathologist utilising a standard methodology
2. The duration of pathologist reporting time
3. Overall costs including device, pathology processing and pathology lab time

Completion date

30/11/2018

Eligibility

Key inclusion criteria

Planned Sample Size: 108; UK Sample Size: 108

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. A greater than 50% cystic component to the pancreatic mass
2. Any contraindication to pancreatic biopsy
3. Patients with a metal biliary stent in situ and target lesion in the head of pancreas
4. Less than 18 years of age
5. Unable and unwilling to give consent
6. Unwilling to undergo additional biopsies
7. Unable to understand English
8. Pregnancy

Date of first enrolment

22/05/2017

Date of final enrolment

04/05/2018

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Freeman Hospital

Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN

Sponsor information

Organisation

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

ROR

<https://ror.org/05p40t847>

Funder(s)

Funder type

Industry

Funder Name

Covidien plc

Funder Name

Medtronic Ltd

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No